RESEARCH / PARTICIPATIONBack to the library
← Find a study
Recruiting · registry status

Following symptom changes during treatment in Belgium

Researchers follow adults with advanced Parkinson’s receiving foslevodopa and foscarbidopa under the skin to study changes in symptoms.

Learning by observing or collecting information · Study reference: NCT07382440

Plain-language introduction written with AI from the registry; not independently checked by a clinician. Read the original details below ↓

Open the official registry record ↗

Follow this study

Looking for volunteers

Start (reported actual date)
2026-03-09
Main measurements finished (planned)
2028-09
Study finished (planned)
2028-09

Planned dates can move. A study finishing does not tell us when a paper will be published.

No results summary has been confirmed in the registry records we imported. See connected papers below; we keep checking after recruitment ends.

Changes we have recorded
  • 2026-10-11 — recruiting

These are dates we observed a change, not necessarily the dates it happened.

Papers connected to this study

No connected paper has been found yet. The tracker checks the growing library for study identifiers and registry-linked publications.

Who can join?

Age 18 years and over · Does not accept healthy volunteers

These are starting points, not the full rules. The research team can tell you whether the study is right for your situation.

Read all the rules for taking part

Sex eligibility reported by registry: all

Inclusion Criteria: * Participant diagnosed with Advanced Parkinson's Disease (PD), aged 18 years or older able to provide voluntary informed consent. * Participant evaluated for commercially available continuous subcutaneous Foslevodopa/Foscarbidopa (LDp/CDp) in the hospital at the clinician's discretion as part of his/her routine clinical care and the intention to administer subcutaneous LDp/CDp made prior to and independent of recruitment into the study. Exclusion Criteria: * Participant participating in an interventional research study (not including noninterventional studies) during the administration of LDp/CDp. * Participant evaluated for commercially available continuous subcutaneous LD/CDp outside of the hospital.
Full study name & original research details

Official study title

Observational Prospective Study to Evaluate Effectiveness of Subcutaneous Treatment With Foslevodopa/Foscarbidopa in Real Life Setting for Advanced Parkinson's Disease Patients in Belgium.

Short title used by the registry

A Study to Assess Change in Disease Symptoms in Adult Participants With Advanced Parkinson Disease Using Subcutaneous Foslevodopa/Foscarbidopa in Belgium

Original description

Parkinson's disease (PD) is a neurological condition, which affects the brain. PD gets worse over time, but how quickly it progresses varies a lot from person to person. Some symptoms of PD are tremors, stiffness, and slowness of movement. This study will assess how effective Foslevodopa/Foscarbidopa is in treating adult participants with advanced Parkinson Disease under routine clinical practice in Belgium. Foslevodopa/Foscarbidopa is an approved drug for the treatment of Parkinson's Disease. Approximately 120 adult participants who are prescribed Foslevodopa/Foscarbidopa by their doctors will be enrolled at 15 sites across Belgium. Participants will receive Foslevodopa/Foscarbidopa subcutaneous infusion as prescribed by their physician. Participants will be followed for up to 18 months. There is expected to be no additional burden for participants in this trial. Participants will attend regular visits during the study at a hospital or clinic according to their routine clinical practice.

Conditions reported: Parkinson's Disease

Registry records for this study

Records are joined using registration identifiers. Titles alone do not establish that two studies are the same.

Study type
Observational
Interventions
Not reported
Phases
Not reported
Sponsor
AbbVie
Start date reported by registry
2026-03-09 (actual)

Registry updated: 2026-07-10 · Status last verified by the registry submitter: 2026-07

Registry records retrieved 2026-10-11 (UTC). Individual records may have older updates. Recruitment and eligibility must be confirmed with the study team.

Contact the research team

Public study contacts supplied to the registry. Ask whether recruitment is still open and what participation involves.

Clementine Semanaz · 844-663-3742 · clementine.semanaz@abbvie.com

Study locations

Site status can differ from overall study status. “Status not reported” means local availability needs confirmation. Remote participation and travel arrangements must be checked with the team.

Imelda Ziekenhuis /ID# 279436

Bonheiden, Antwerpen, Belgium

Recruiting

Universitair Ziekenhuis Antwerpen /ID# 279434

Edegem, Antwerpen, Belgium

Recruiting

Chu Tivoli /ID# 279455

La Louvière, Hainaut, Belgium

Recruiting

Centre Hospitalier De Wallonie Picarde - Site Notre Dame /ID# 279452

Tournai, Hainaut, Belgium

Recruiting

Jessa Ziekenhuis - Campus Virga Jesse /ID# 279454

Hasselt, Limburg, Belgium

Recruiting

AZ Sint-Lucas /ID# 279453

Ghent, Oost-Vlaanderen, Belgium

Recruiting

UZ Gent /ID# 279433

Ghent, Oost-Vlaanderen, Belgium

Recruiting

Universitair Ziekenhuis Leuven /ID# 279439

Leuven, Vlaams-Brabant, Belgium

Recruiting

Algemeen Ziekenhuis Sint-Jan Brugge /ID# 279422

Bruges, West-Vlaanderen, Belgium

Recruiting

Az Groeninge Campus Kennedylaan /ID# 279423

Kortrijk, West-Vlaanderen, Belgium

Recruiting

AZ Oostende /ID# 279461

Ostend, West-Vlaanderen, Belgium

Recruiting

AZ-Delta. /ID# 279437

Roeselare, West-Vlaanderen, Belgium

Recruiting

Facility not reported

Belgium

Status not reported

The original descriptions and participation rules come from the registry. Participation is voluntary and does not guarantee benefit.